Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Dianthus Therapeutics has reported Cash & Equivalents for 9 years, with the latest figure at $50.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 128.96% year-over-year to $50.2 million; the trailing twelve-month figure through Dec 2025 stood at $50.2 million (up 128.96% YoY), and the FY2025 full-year result was $50.2 million, up 128.96% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $50.2 million, down from $56.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $329.7 million in Q1 2024, with the low at $10.1 million in Q1 2025.
• Average Cash & Equivalents over 5 years is $92.7 million, with a median of $52.5 million recorded in 2022.
• Year-over-year, Cash & Equivalents jumped 1320.49% in 2024 and tumbled 96.93% in 2025.
• Tracing DNTH's Cash & Equivalents over 5 years: stood at $131.6 million in 2021, then slumped by 88.33% to $15.4 million in 2022, then jumped by 761.21% to $132.3 million in 2023, then slumped by 83.42% to $21.9 million in 2024, then soared by 128.96% to $50.2 million in 2025.
• The last three Cash & Equivalents figures came in at $50.2 million (Q4 2025), $56.0 million (Q3 2025), and $12.0 million (Q2 2025), per Business Quant data.

Peer Comparison